. Author manuscript; available in PMC: 2025 Mar 1.

Published in final edited form as: Muscle Nerve. 2024 Jan 8;69(3):362–367. doi: 10.1002/mus.28031

Table 2.

Changes in Strength, Lean Body Mass, Functional, and Patient-Reported Outcomes from Baseline to 12 Months

Outcome Measure	Mean ± SD change	95% confidence interval	p-value
Average MMT Score	−0.03 ± 0.11	(−0.06, 0.01)	0.11
Average Standardized MVICT Score	−0.43 ± 1.11	(−0.80, −0.06)	0.02
Average Standardized MVICT Score (Upper)	−0.53 ± 1.38	(−0.99, −0.07)	0.03
Average Standardized MVICT Score (Lower)	−0.28 ± 0.90	(−0.59, 0.02)	0.06
DEXA Lean Body Mass	−0.33 ± 1.04	(−0.76, 0.10)	0.12
FSHD-COM	0.27 ± 3.45	(−0.94, 1.47)	0.66
FSHD Clinical Severity Score (CSS)	0.13 ± 1.04	(−0.21, 0.48)	0.44
FSHD Evaluation Score (FES)	0.32 ± 1.21	(−0.08, 0.71)	0.12
FSHD-HI Total Score	−3.03 ± 9.96	(−6.26, 0.20)	0.07